Opioid plasma concentrations in methadone‐and buprenorphine‐maintained patients

This is the first trial to compare the relationship of opioid plasma concentrations in methadone‐versus buprenorphine‐maintained subjects. Sixty subjects (19 females and 41 males) seeking treatment who met Diagnostic and Statistical Manual version IV (DSM‐IV) criteria for opioid dependence were recruited and treated at the Drug Addiction Outpatient Clinic at the University of Vienna. Of these, 44 (11 female and 33 male) were included in the analyses of plasma concentrations. Subjects received either daily sublingual buprenorphine (2mg or 8mg tablets; maximum daily dose: 8mg) or oral methadone (racemic R‐/S‐methadone) and were maintained on a stable dose after an induction period of 2 weeks. Mean dose and mean plasma concentrations were correlated on an individual and collective basis. Correlation was 0.51 for buprenorphine, whereas the score for methadone was 0.69. Intra‐individual variation was much higher for buprenorphine (p < 0.0001), while the concentration‐to‐dose ratio was very small. Based on the differences of the pharmacokinetics of blood plasma of the two agents, we tried to explain the differences in the acceptance of treatment, which was significantly lower in the buprenorphine‐maintained group. No such differences could be evaluated between completers and dropouts in buprenorphine‐maintained subjects, neither concerning withdrawal scores nor dose, plasma concentration, concentration‐to‐dose ratios or intra‐individual variation.

[1]  H. Emrich,et al.  Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone , 2005, Addiction biology.

[2]  C. N. Chiang,et al.  Pharmacokinetics of the combination tablet of buprenorphine and naloxone. , 2003, Drug and alcohol dependence.

[3]  N. Mello,et al.  Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. , 2003, Drug and alcohol dependence.

[4]  E. Strain,et al.  A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. , 2002, Analytical biochemistry.

[5]  J. Gardner-Nix.  Opioids causing peripheral edema. , 2002, Journal of pain and symptom management.

[6]  R. Jagsch,et al.  Buprenorphine versus methadone maintenance for the treatment of opioid dependence , 1999, European Neuropsychopharmacology.

[7]  R. de la Torre,et al.  Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program. , 1998, Drug and alcohol dependence.

[8]  W. Ling,et al.  Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. , 1998, Addiction.

[9]  D J Crouch,et al.  Determination of buprenorphine in human plasma by gas chromatography-positive ion chemical ionization mass spectrometry and liquid chromatography-tandem mass spectrometry. , 1997, Journal of analytical toxicology.

[10]  D. Ziedonis,et al.  Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. , 1997, Archives of general psychiatry.

[11]  J. Mendelson,et al.  P300 assessment of opiate and cocaine users: Effects of detoxification and buprenorphine treatment , 1996, Biological Psychiatry.

[12]  R. Foltz,et al.  Determination of methadone and its N-demethylation metabolites in biological specimens by GC-PICI-MS. , 1996, Journal of analytical toxicology.

[13]  M. Willenbring,et al.  Reliability of Methadone Plasma Levels in Methadone Maintenance , 1995 .

[14]  M. Stitzer,et al.  Comparison of buprenorphine and methadone in the treatment of opioid dependence. , 1994, The American journal of psychiatry.

[15]  K. Preston,et al.  Clinical pharmacology of buprenorphine: Ceiling effects at high doses , 1994, Clinical pharmacology and therapeutics.

[16]  N. Loimer,et al.  The use of plasma levels to optimize methadone maintenance treatment. , 1992, Drug and alcohol dependence.

[17]  J. Jaffe,et al.  A controlled trial of buprenorphine treatment for opioid dependence. , 1992, JAMA.

[18]  M. Feely,et al.  Measuring compliance in methadone maintenance patients: Use of a pharmacologic indicator to “estimate” methadone plasma levels , 1991, Clinical pharmacology and therapeutics.

[19]  W. Bickel,et al.  A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts , 1988, Clinical pharmacology and therapeutics.

[20]  R. Moore,et al.  Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. , 1982, British journal of clinical pharmacology.

[21]  D. Jasinski,et al.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. , 1978, Archives of general psychiatry.

[22]  Richard I. H. Wang,et al.  Rating the presence and severity of opiate dependence , 1974, Clinical pharmacology and therapeutics.

[23]  M. Kreek.  Medical safety and side effects of methadone in tolerant individuals. , 1973, JAMA.

[24]  V. Dole,et al.  A Medical Treatment for Diacetylmorphine (Heroin) Addiction , 1966 .

[25]  V. Dole,et al.  A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE. , 1965, JAMA.

[26]  M. M. Eisenberg.  Surgery of the Gall Bladder and Bile Ducts , 1965 .

[27]  K. Wolff,et al.  Methadone concentrations in plasma and their relationship to drug dosage. , 1991, Clinical Chemistry.

[28]  G. Woody,et al.  Methadone and edema. , 1991, Journal of substance abuse treatment.

[29]  Pedro Parraguez Ruiz,et al.  Methadone treatment and physical complaints: a clinical analysis. , 1981, The International journal of the addictions.